The estimated Net Worth of Christopher Y Chai is at least $1.02 Million dollars as of 18 August 2020. Christopher Chai owns over 7,500 units of Principia Biopharma stock worth over $36,815 and over the last 5 years Christopher sold PRNB stock worth over $982,425.
Christopher has made over 3 trades of the Principia Biopharma stock since 2020, according to the Form 4 filled with the SEC. Most recently Christopher exercised 7,500 units of PRNB stock worth $22,500 on 18 August 2020.
The largest trade Christopher's ever made was exercising 7,500 units of Principia Biopharma stock on 18 August 2020 worth over $22,500. On average, Christopher trades about 4,500 units every 36 days since 2020. As of 18 August 2020 Christopher still owns at least 11,039 units of Principia Biopharma stock.
You can see the complete history of Christopher Chai stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at Principia Biopharma have traded over $44,614,108 worth of Principia Biopharma stock and bought 1,381,884 units worth $39,224,700 . The most active insiders traders include Plc Gsk, Patrick Machado, and Partners L P/Ilbiotechnolog.... On average, Principia Biopharma executives and independent directors trade stock every 17 days with the average trade being worth of $330,499. The most recent stock trade was executed by Roy C. Hardiman on 18 September 2020, trading 5,000 units of PRNB stock currently worth $29,300.
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immune-mediated diseases. The company is developing rilzabrutinib, an inhibitor that is in Phase III clinical trials for the treatment of pemphigus, a chronic skin disease, as well as and pemphigus foliaceus; in a Phase 1/2 trial for the treatment of immune thrombocytopenia; and a Phase 2 trial for the treatment of IgG4-related disease. It is also developing PRN2246/SAR442168, an inhibitor, which is in Phase Ii clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; and PRN473, a drug candidate that is in Phase I clinical trial for the treatment of immune-medicated diseases. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
Principia Biopharma executives and other stock owners filed with the SEC include: